vimarsana.com

Page 2 - Co Diagnostic Chief Executive Officer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Co-Diagnostics, Inc Reports Full Year 2022 Financial Results

/PRNewswire/ Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular.

United statesNoriko kusukawaAnne wyllieDwight eganKarenc carrollCarl wittwerExchange commissionDiagnostics incInitiation of clinical evaluations for coBio molecular systems for the coPrnewswire coFull year results impactedSlower demandClinical evaluationsLogix smartCo diagnostic chief executive officer

Co-Diagnostics, Inc Reports Third Quarter 2022 Financial Results

/PRNewswire/ Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular.

United statesMark poritzDwight eganExchange commissionDiagnostics incCo diagnostic chief executive officerRecent business highlightsMonekypox virusBio molecularChief scientificLooking statementsRisk factorsAnnual reportMonths ended september

Co-Diagnostics, Inc Reports Third Quarter 2022 Financial Results

/PRNewswire/ Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular.

United statesMark poritzDwight eganExchange commissionDiagnostics incCo diagnostic chief executive officerRecent business highlightsMonekypox virusBio molecularChief scientificLooking statementsRisk factorsAnnual reportMonths ended septemberCo diagnostics

Co-Diagnostics, Inc Reports Second Quarter 2022 Financial Results

/PRNewswire/ Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular.

United statesDwight eganExchange commissionDiagnostics incPrnewswire coLogix smartCo diagnostic chief executive officerRecent business highlightsBio molecular systemsCo dx boxLooking statementsRisk factorsAnnual reportMonths ended juneCo diagnostics

Co-Diagnostics, Inc Reports Second Quarter 2022 Financial Results

Second quarter results impacted by volume declines; Further progress on the development of the Co-Dx PCR Home platformSALT LAKE CITY, Aug. 11, 202.

United statesDwight eganExchange commissionDiagnostics incPrnewswire coLogix smartCo diagnostic chief executive officerRecent business highlightsBio molecular systemsCo dx boxAbout co diagnosticsForward looking statementsRisk factorsAnnual reportMonths ended june

vimarsana © 2020. All Rights Reserved.